Overview
Voriconazole Compared With Itraconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Status:
Completed
Completed
Trial end date:
1969-12-31
1969-12-31
Target enrollment:
0
0
Participant gender:
All
All
Summary
RATIONALE: Antifungals, such as voriconazole and itraconazole, may be effective in preventing fungal infections in patients who are undergoing allogeneic stem cell transplantation. PURPOSE: This randomized clinical trial is studying voriconazole to see how well it works compared to itraconazole in preventing fungal infections in patients who are undergoing allogeneic hematopoietic stem cell transplantation.Phase:
N/AAccepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Jonsson Comprehensive Cancer CenterCollaborator:
National Cancer Institute (NCI)Treatments:
Hydroxyitraconazole
Itraconazole
Voriconazole
Criteria
DISEASE CHARACTERISTICS:- Undergoing allogeneic hematopoietic stem cell transplantation
- No invasive yeast infection within the past 8 weeks
- Colonized or superficial infection allowed
- No documented or probable aspergillus or mold infection within the past 8 weeks
- Patients with a history of candidemia must have negative blood cultures and no
clinical signs of candidemia
PATIENT CHARACTERISTICS:
Age
- 12 and over
Performance status
- Not specified
Life expectancy
- Not specified
Hematopoietic
- Not specified
Hepatic
- Not specified
Renal
- Not specified
Other
- Not pregnant or nursing
- Fertile patients must use effective contraception
- No prior allergy or intolerance to imidazoles or azoles (e.g., fluconazole,
itraconazole, voriconazole, ketoconazole, miconazole, or clotrimazole)
PRIOR CONCURRENT THERAPY:
Biologic therapy
- See Disease Characteristics
Chemotherapy
- Not specified
Endocrine therapy
- Not specified
Radiotherapy
- Not specified
Surgery
- Not specified
Other
- At least 1 week since prior amphotericin B or fluconazole for candidemia
- No concurrent therapy with any of the following:
- Rifampin
- Rifabutin
- Phenobarbital
- Phenytoin
- Carbamazepine
- Oral midazolam
- Triazolam
- Terfenadine
- Astemizole
- Concurrent topical antifungal agents for superficial fungal infections allowed